TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05035524
Drug: Sodium Bicarbonate Solution
Normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inhalation of SB 8.4% via a jet nebulizer (5 ml every 4 h) starting at 7:00 to 23:00 hours every day for 30 days together with instillation of SB 8.4% drops 4-times daily (three drops for each nostril) were offered to all patients in the study group (El-Badrawy et al., 2019).
Study: NCT05091567
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin will be administered according to the standard of care treatment for 4 cycles in the induction phase.
Study: NCT05091567
Drug: Etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Etoposide will be administered according to the standard of care treatment for 4 cycles in the induction phase.
Study: NCT05800015
Drug: fianlimab
Normalized name: Fianlimab
DrugBank: Fianlimab (DB18858)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered intravenously (IV) every 3 weeks (Q3W)
Study: NCT00040586
Drug: Monoclonal Antibody J591
Normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT04073472
Drug: mesenchymal stem cells (MSCs)
Normalized name: Autologous adipose derived mesenchymal stem cells (MSCS)
DrugBank: Human Umbilical Cord Mesenchymal Stem Cells (DB15726)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allogeneic bone marrow derived mesenchymal stem cells (MSCs) direct injection to an ileal pouch fistula in the setting of Crohn's disease of the pouch
Study: NCT05800015
Drug: cemiplimab
Normalized name: CEMIPLIMAB
DrugBank: Cemiplimab (DB14707)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Administered IV Q3W
Study: NCT05800015
Drug: Pemetrexed
Normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: IV Infusion, Q3W
Study: NCT05800015
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: IV Infusion, Q3W
Study: NCT00040586
Drug: Recombinant Interleukin-2
Normalized name: Recombinant interleukin-2 human
DrugBank: Aldesleukin (DB00041)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05800015
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV Infusion, Q3W
Study: NCT05800015
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV infusion, Q3W
Study: NCT06139211
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxaliplatin will be administered intravenously (IV) on day 1 every 21 day cycle.
Study: NCT04914247
Drug: Selexipag
Normalized name: Selexipag
DrugBank: Selexipag (DB11362)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT05095961
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5 day course of oral prednisone pre-operatively. 30mg per day.
Study: NCT06139211
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine will be administered intravenously (IV) on days 1 and 8 every 21 day cycle.
Study: NCT06139211
Drug: Albumin-Bound Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Albumin-bound paclitaxel will be administered intravenously (IV) on days 1 and 8 every 21 day cycle.
Study: NCT06417229
Drug: BMS-986365
Normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Specified dose on specified days
Study: NCT06417229
Drug: Rabeprazole
Normalized name: Rabeprazole
DrugBank: Rabeprazole (DB01129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Specified dose on specified days
Study: NCT05508334
Drug: RC88
Normalized name: RC88
DrugBank: RC88 (DB18697)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Every 2 weeks for a maximum of 2 years
Study: NCT04760860
Drug: Terazosin Hydrochloride
Normalized name: Terazosin Hydrochloride
DrugBank: Terazosin (DB01162)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In this double blind, randomized, placebo controlled phase I clinical trial, subjects randomized into the Terazosin group will receive Terazosin hydrochloride treatment for 15 weeks. Participants will start at 1mg daily for the first 6 week, then the dosage will be increased to 5mg daily over 3 weeks, and continued for the last 6 weeks.
Study: NCT05756166
Drug: Rintatolimod
Normalized name: Rintatolimod
DrugBank: Rintatolimod (DB16425)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT06387303
Drug: Methadone
Normalized name: Methadone
DrugBank: Methadone (DB00333)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous Methadone
Study: NCT06387303
Drug: Morphine
Normalized name: Morphine
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrathecal Morphine
Study: NCT05935358
Drug: Nuwiq
Normalized name: Nuwiq
DrugBank: Simoctocog alfa (DB09108)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Nuwiq is a purified B-domain-deleted FVIII glycoprotein synthesised by a genetically engineered human embryonic kidney cell line (HEK 293F).
Study: NCT02141087
Drug: Pirfenidone
Normalized name: Pirfenidone
DrugBank: Pirfenidone (DB04951)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT05696613
Drug: SNP-ACTH (1-39) Gel
Normalized name: ACTH
DrugBank: SNP-ACTH (1-39) (DB18544)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be randomly assigned in 1:1 treatment allocation ratio to receive the test and reference product.
Study: NCT05696613
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subjects will be randomly assigned in 1:1 treatment allocation ratio to receive the test and reference product.
Study: NCT06327100
Drug: Ruxolitinib
Normalized name: Ruxolitinib
DrugBank: Ruxolitinib (DB08877)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given by PO
Study: NCT06327100
Drug: Tasquinimod
Normalized name: Tasquinimod
DrugBank: Tasquinimod (DB05861)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given by PO
Study: NCT05491616
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: In this SANO-3 study, patients will receive Nivolumab at 480mg Q4W starting 10-14 weeks after nCRT (i.e., when cCR has been established) until disease progression or unacceptable toxicity, for a maximum duration of 1 year.
Study: NCT04907370
Drug: PD-1 blocking antibody
Normalized name: Humanized pd-1 blocking antibody hx-008
DrugBank: Pucotenlimab (DB17552)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1. IC phase of PD-1 blocking antibody: every 3 weeks × 3 cycles; 240 mg, day 1; start on day 1 of the first cycle IC and continue every 3 weeks for 3 cycles till the end of IC.~2. IMRT phase of PD-1 blocking antibody: every 3 weeks × 3 cycles; 240 mg, day 1; start on day 1 of IMRT or CCRT and continue every 3 weeks for 3 cycles till the end of IMRT.~3. Adjuvant PD-1 blocking antibody: every 3 weeks × 11 cycles; 240 mg, day 1
Study: NCT04907370
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine as induction chemotherapy, 1000 mg/m2 day 1, 8 per cycle, every 3 weeks for 3 cycles
Study: NCT04907370
Drug: Cisplatin (80mg/m2)
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin as induction chemotherapy, 80 mg/m2 day 1 per cycle, every 3 weeks for 3 cycles
Study: NCT04907370
Drug: Cisplatin (100mg/m2)
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin as concurrent chemotherapy, 100 mg/m2 day 1 per cycle, every 3 weeks for 2 cycles
Study: NCT01250808
Drug: Bortezomib/Dexamethasone/Melphalan
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Induction therapy: The treatment will continue for 3-4 cycles and each cycle will be last 21 days.~Bortezomib 1.3mg/m2, twice weekly for two weeks (days 1, 4, 8, and 11) of each cycle + Dexamethasone 20mg/m2, on days 1-4 of each cycle.~Bortezomib 1.0mg/m2, twice weekly for two weeks (days 1, 4, 8, and 11) of each cycle + Dexamethasone 20mg/m2, on days 1-4 of each cycle.~Bortezomib 1.6mg/m2, once weekly for two weeks (days 1, 8) of each cycle + Dexamethasone 20mg/m2, on days 1-4 of each cycle and on days 9-12 of the first and second cycles.~ASCT therapy:~Melphalan 200mg/m2 +Bortezomib 1.0mg/m2 for four times. Melphalan 200mg/m2 +Bortezomib 1.0mg/m2 for two times.
Study: NCT05252546
Drug: pyrotinib tablet
Normalized name: Pyrotinib
DrugBank: Pyrotinib (DB14993)
Approvals — FDA: no, EMA: no, PMDA: no
Description: single oral dose of pyrotinib or co-administered with Montmorillonite Power or Loperamide
Study: NCT05252546
Drug: Montmorillonite Power
Normalized name: Montmorillonite
DrugBank: Montmorillonite (DB13654)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g or one pouch of montmorillonite power 2 hours after pyrotinib administration
Study: NCT05252546
Drug: Loperamide
Normalized name: Loperamide
DrugBank: Loperamide (DB00836)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4 mg of loperamide with pyrotinib followed by 2mg every 2 hours for 2 times for a total of 8mg/day
Study: NCT05123482
Drug: AZD8205 and AZD2936 (Rilvegostomig)
Normalized name: cytarabine and daunorubicin
DrugBank: Daunorubicin (DB00694)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: AZD8205 is an antibody drug conjugate that has the potential to treat a wide variety of solid tumors including but not limited to breast cancer, Biliary Tract Cancer, ovarian, endometrial cancers and squamous non-small cell lung cancers.~Rilvegostomig is a bispecific antibody that specifically binds to human TIGIT and PD-1 and is a potential anticancer therapy in patients with advanced or metastatic solid tumors.
Study: NCT05123482
Drug: AZD8205 and AZD5305 (saruparib)
Normalized name: cytarabine and daunorubicin
DrugBank: Daunorubicin (DB00694)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: AZD8205 is an antibody drug conjugate that has the potential to treat a wide variety of solid tumors including but not limited to breast cancer, Biliary Tract Cancer, ovarian, endometrial and squamous non-small cell lung cancers.~Saruparib is a PARP inhibitor that stops the PARP protein from doing its repair work in damaged cancer cells, resulting in cell death, and is a potential anticancer therapy in patients with advanced or metastatic solid tumors.
Study: NCT05123482
Drug: AZD8205 and AZD5305 (saruparib) and AZD2936 (rilvegostomig)
Normalized name: cytarabine and daunorubicin
DrugBank: Daunorubicin (DB00694)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: AZD8205 is an antibody drug conjugate that has the potential to treat a wide variety of solid tumors including but not limited to breast cancer, Biliary Tract Cancer, ovarian, endometrial and squamous non-small cell lung cancers.~Saruparib is a PARP inhibitor that stops the PARP protein from doing its repair work in damaged cancer cells, resulting in cell death, and is a potential anticancer therapy in patients with advanced or metastatic solid tumors.~Rilvegostomig is a bispecific antibody that specifically binds to human TIGIT and PD-1 and is a potential anticancer therapy in patients with advanced or metastatic solid tumors.
Study: NCT05027295
Drug: riboflavin ophthalmic solution
Normalized name: riboflavin 5'-phosphate Ophthalmic Product
DrugBank: Riboflavin (DB00140)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administration of riboflavin one drop every 2 minutes during administration of continuous UVA light for 7.5 minutes.
Study: NCT05027295
Drug: riboflavin ophthalmic solution
Normalized name: riboflavin 5'-phosphate Ophthalmic Product
DrugBank: Riboflavin (DB00140)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administration of riboflavin one drop every 2 minutes during administration of pulsed UVA light for 15 minutes
Study: NCT06313255
Drug: PegIFNα2b
Normalized name: Interferon α-2b
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The patients receive PegIFNα2b therapy
Study: NCT05794581
Drug: CT-868
Normalized name: CT-179
DrugBank: CT-179 (DB17114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CT-868
Study: NCT05794581
Drug: Victoza
Normalized name: Victoza
DrugBank: Liraglutide (DB06655)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Victoza as active comparator as SC Injection
Study: NCT06131255
Drug: Citalopram
Normalized name: Citalopram
DrugBank: Citalopram (DB00215)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will be administered citalopram, regardless of inclusion or non-inclusion in this study, on medical indication, as per normal clinical practice for disease management and according to the Summary of Product Characteristics (SPC). Patients will have two MRI scans done (at baseline and at 12 weeks after the start of therapy) to assess: brain volumetry, tissue amount of gray matter - GM - and white matter - WM
Study: NCT05137587
Drug: propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: propofol
Study: NCT05137587
Drug: ketamine
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ketamine
Study: NCT04973566
Drug: Nipocalimab
Normalized name: Nipocalimab
DrugBank: Nipocalimab (DB16257)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nipocalimab will be administered as an IV infusion.
Study: NCT04973566
Drug: Etanercept
Normalized name: Etanercept
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Etanercept will be administered subcutaneously.
Study: NCT04973566
Drug: Hydroxychloroquine
Normalized name: Hydroxychloroquine
DrugBank: Hydroxychloroquine (DB01611)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: HCQ will be administered orally.
Study: NCT06525298
Drug: EIS-12656
Normalized name: BLACK-EYED PEA
DrugBank: Black-eyed pea (DB10663)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EIS-12656 tablets given daily
Study: NCT06525298
Drug: Olaparib
Normalized name: Olaparib
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: as per USPI/SmPC
Study: NCT06525298
Drug: Trastuzumab deruxtecan
Normalized name: Trastuzumab deruxtecan
DrugBank: Trastuzumab deruxtecan (DB14962)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: as per USPI/SmPC
Study: NCT05559450
Drug: Blinatumomab
Normalized name: Blinatumomab
DrugBank: Blinatumomab (DB09052)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Blinatumomab will be bridged to conventional BUCY conditioning regimen.
Study: NCT04715191
Drug: Cytoxan
Normalized name: Cytoxan
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide will be given at a dose of 500 mg/m2/day for 3 days given intravenously.
Study: NCT04715191
Drug: Fludara
Normalized name: Fludara
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fludarabine will be given at a dose of 30 mg/m2/day for 3 days given intravenously.
Study: NCT05372640
Drug: Abemaciclib
Normalized name: Abemaciclib
DrugBank: Abemaciclib (DB12001)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT05372640
Drug: BET Bromodomain Inhibitor ZEN-3694
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT04952610
Drug: Etripamil NS 70 mg
Normalized name: NS-2359
DrugBank: Etripamil (DB12605)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etripamil will be administered via the Aptar Pharma Nasal Spray Bidose System.
Study: NCT05568615
Drug: MT-1186
Normalized name: lipase
DrugBank: Pancrelipase (DB00085)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suspension
Study: NCT06474182
Drug: Apixaban
Normalized name: Apixaban
DrugBank: Apixaban (DB06605)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Treatment by Apixaban
Study: NCT06082934
Drug: Olverembatinib plus venetoclax and dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Olverembatinib: orally every other day at a dose of 40mg Venetoclax: in a daily ramp-up strategy (100 mg d4, 200 mg d5, 400 mg d6-17) Dexamethasone: intravenously 10mg, d1-14, 5mg, d15-28
Study: NCT06652607
Drug: Enzalutamide
Normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The objective of the study is to assess survival in patients treated with Enzalutamide according to PSA response and to describe the baseline characteristics of patients with and without an optimal PSA response.
Study: NCT06652607
Drug: Apalutamide (Erleada™) 60 mg or 240 mg tablets
Normalized name: apalutamide 60 MG
DrugBank: Apalutamide (DB11901)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: The objective of the study is to assess survival in patients treated with Apalutamide according to PSA response and to describe the baseline characteristics of patients with and without an optimal PSA response.
Study: NCT06652607
Drug: Darolutamide (Nubeqa®) 300 mg tablets
Normalized name: darolutamide
DrugBank: Darolutamide (DB12941)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: The objective of the study is to assess survival in patients treated with Darolutamide according to PSA response and to describe the baseline characteristics of patients with and without an optimal PSA response.
Study: NCT06652607
Drug: Taxotere (docetaxel)
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The objective of the study is to assess survival in patients treated with Taxotere according to PSA response and to describe the baseline characteristics of patients with and without an optimal PSA response.
Study: NCT06652607
Drug: Abiraterone acetate + Prednisone or Prednisolone
Normalized name: Abiraterone Acetate
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: The objective of the study is to assess survival in patients treated with Abiraterone according to PSA response and to describe the baseline characteristics of patients with and without an optimal PSA response.
Study: NCT05280340
Drug: Anakinra
Normalized name: ANAKINRA
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Anakinra will be given to enrolled infants starting in the first 24hrs of life for the first 3 weeks of life.
Study: NCT06326645
Drug: Crofelemer Oral Product
Normalized name: crofelemer Oral Product
DrugBank: Crofelemer (DB04941)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Crofelemer powder for solution (50g and 100g) or Crofelemer Powder for Oral Solution (100 mg/mL or 30 mg/mL vials for reconstitution and oral dosing)
Study: NCT06513338
Drug: Eculizumab
Normalized name: Eculizumab
DrugBank: Eculizumab (DB01257)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: eculizumab 900mg iv. per week for 4 weeks, then 1200mg every two weeks for week 5 to. week 11
Study: NCT05953610
Drug: Acetazolamide 500 MG QHS
Normalized name: acetazolamide 500 MG
DrugBank: Acetazolamide (DB00819)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetazolamide
Study: NCT05953610
Drug: Eszopiclone 3 mg QHS
Normalized name: eszopiclone 3 MG
DrugBank: Eszopiclone (DB00402)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eszopiclone
Study: NCT05051436
Drug: Mirabegron 50 MG
Normalized name: mirabegron 50 MG
DrugBank: Mirabegron (DB08893)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mirabegron 50 mg/day will be administered for 14 weeks.
Study: NCT05051436
Drug: Tadalafil 10 MG
Normalized name: tadalafil 10 MG
DrugBank: Tadalafil (DB00820)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tadalafil 10 mg/day will be administered for 14 weeks after baseline procedures.
Study: NCT05331521
Drug: CETEG
Normalized name: Cetirizine
DrugBank: Cetirizine (DB00341)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: At progression, patients without prior radiotherapy will undergo radiotherapy and PCV as an adjunct chemotherapy if bone marrow reserve allows in the experimental arm.
Study: NCT05331521
Drug: PCV
Normalized name: PCV
DrugBank: Penciclovir (DB00299)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In the comparator arm there is the option for second radiotherapy or even reuse of the full radiochemotherapy regimen as it had been given at diagnosis (BIC).
Study: NCT04955236
Drug: Partial scalp block
Normalized name: Ivy Block
DrugBank: Bentoquatam (DB00516)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Partial scalp blocks will be performed bilaterally after assuming the prone position.The Greater occipital will be blocked by injecting 3ml of local anaesthetic at a point half way between the mastoid process the external occipital protuberance along the superior nuchal line, medial to the occipital artery. The Lesser occipital nerve will be blocked by injecting 3ml of local anaesthetic infiltration along the superior nuchal line, 2.5 cm lateral to the greater occipital nerve block. The greater occipital nerve block also will cover the third occipital nerve due to the close location of the two nerves.~A placebo infusion (normal saline) will be administered at the same rate as fentanyl infusion in the active comparator arm(1 µg/kg/hr.).
Study: NCT06439056
Drug: NEX-22A, a prolonged release formulation of liraglutide
DrugBank: Liraglutide (DB06655)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: NEX-22A, a prolonged release formulation of liraglutide
Study: NCT05916313
Drug: BI 764532
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 764532
Study: NCT06215118
Drug: Elranatamab
Normalized name: ELRANATAMAB
DrugBank: Elranatamab (DB15395)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCMA-CD3 bispecific antibody
Study: NCT06215118
Drug: Iberdomide
Normalized name: Iberdomide
DrugBank: Iberdomide (DB12101)
Approvals — FDA: no, EMA: no, PMDA: no
Description: cereblon-modulating agent
Study: NCT05019430
Drug: Cocaine
Normalized name: Cocaine
DrugBank: Cocaine (DB00907)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The pharmacodynamic effects of cocaine will be determined during maintenance on placebo and zolmitriptan.
Study: NCT05019430
Drug: Zolmitriptan
Normalized name: Zolmitriptan
DrugBank: Zolmitriptan (DB00315)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The pharmacodynamic effects of zolmitriptan maintenance will be determined.
Study: NCT04945330
Drug: Larotrectinib (Vitrakvi, BAY2757556)
Normalized name: larotrectinib 100 MG [Vitrakvi]
DrugBank: Larotrectinib (DB14723)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Follow clinical practice
Study: NCT05638256
Drug: 68Ga-NY104
Normalized name: 68Ga-DOTATOC
DrugBank: Dotatate gallium Ga-68 (DB13925)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive a tracer (20-40mcg, IV) dose of 68Ga (2-5mCi) labelled NY104
Study: NCT06533475
Drug: Minzasolmin tablet formulation under fasting condition
Normalized name: Minzasolmin
DrugBank: Minzasolmin (DB18961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: Minzasolmin Pharmaceutical form: Tablet formulation under fasting condition
Study: NCT06533475
Drug: Minzasolmin Granules in capsule under fasting condition
Normalized name: Minzasolmin
DrugBank: Minzasolmin (DB18961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: Minzasolmin Pharmaceutical form: Granules in capsule under fasting condition